Association of Innate Immune Responses with SARS-CoV-2 Positivity in Children Under Five Years Old

Main Article Content

Samira Asli
Nafiseh Taheri
Maryam D ehghani Firoozabadi
Hana Askari
Arastoo Vojdani
Elham Babaei
Sajjad Asli
Mohammad Reza Shahami
Saeid Amel Jamehdar

Abstract

Introduction: The innate immune system detects viral RNA via RIG-I and MDA5, triggering type I interferon production. However, the effects of SARS-CoV-2 on these pathways in young children are still unclear. This study compared the expression of RIG-I, MDA5, IFN-α, and IFN-β between SARS-CoV-2-positive and SARS-CoV-2-negative children under five years of age with respiratory symptoms.
Materials and methods: This cross-sectional study included 138 children younger than five years who presented with respiratory symptoms, including fever, cough, and/or rhinorrhea, at Khanevadeh Hospital in Tehran, Iran, between April 6 and November 1, 2022. SARS-CoV-2 infection was identified using real-time reverse-transcription polymerase chain reaction (qRT-PCR) targeting the E and RDRP genes. The relative mRNA levels of RIG-I, MDA5, IFN-α, and IFN-β genes were measured using qRT-PCR, with GAPDH serving as the reference gene. The expression levels were then compared between children who tested positive and those who tested negative for SARS-CoV-2.
Results: Children who tested positive for SARS-CoV-2 had significantly higher IFN-α expression (0.06 ± 0.02 versus 0.04 ± 0.02) and significantly higher MDA5 expression (3.03 ± 1.10 versus 1.98 ± 0.56) than those who tested negative. IFN-β expression did not differ significantly between the two groups (0.07 ± 0.06 versus 0.07 ± 0.08). The RIG-I expression was numerically higher in SARS-CoV-2-positive children, but the difference was not statistically significant.
Conclusion: In children under five years of age with respiratory symptoms, SARS-CoV-2 positivity was linked to higher MDA5 and IFN-α expression, while RIG-I and IFN-β levels did not significantly differ between infected and uninfected participants. The current findings suggested that MDA5-related innate immune signaling may be involved in the early antiviral response to SARS-CoV-2 in young children.

Article Details

How to Cite
Asli, S., Taheri, N., ehghani Firoozabadi, M. D., Askari, H., Vojdani, A., Babaei, E., Asli, S., Shahami, M. R., & Amel Jamehdar, S. (2026). Association of Innate Immune Responses with SARS-CoV-2 Positivity in Children Under Five Years Old. Journal of Lab Animal Research, 5(5), 110–115. Retrieved from https://jlar.rovedar.com/index.php/JLAR/article/view/121
Section
Original Articles
Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020; 96(1142): 753-758. DOI: 10.1136/postgradmedj-2020-138234

Velavan TP, and Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020; 25(3): 278-280. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7169770/pdf/TMI-25-278.pdf

Jain N, Lodha R, and Kabra S. Upper respiratory tract infections. Indian J Pediatr. 2001; 68: 1135-1138. DOI: 10.1007/BF02722930

Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Sig Transduct Target Ther. 2020; 5(1): 128. DOI: 10.1038/s41392-020-00243-2

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91-95. DOI: 10.1016/j.ijid.2020.03.017

Shishido SN, Varahan S, Yuan K, Li X, and Fleming SD. Humoral innate immune response and disease. Clin Immunol. 2012; 144(2): 142-158. DOI: 10.1016/j.clim.2012.06.002

Koyama S, Ishii KJ, Coban C, and Akira S. Innate immune response to viral infection. Cytokine. 2008; 43(3): 336-341. DOI: 10.1016/j.cyto.2008.07.009

Zheng Y, Zhuang MW, Han L, Zhang J, Nan ML, Zhan P, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Sig Transduct Target Ther. 2020; 5(1): 299. DOI: 10.1038/s41392-020-00438-7

Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006; 441(7089): 101-105. DOI: 10.1038/nature04734

Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020; 368(6494): 1012-1015. DOI: 10.1126/science.abb7314

Han L, Zhuang MW, Deng J, Zheng Y, Zhang J, Nan ML, et al. SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways. J Med Virol. 2021; 93(9): 5376-5389. DOI: 10.1002/jmv.27050

Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med. 2020; 217(12): e20201241. DOI: 10.1084/jem.20201241

Nahavandi-Parizi P, Kariminik A, and Montazeri M. Retinoic acid-inducible gene 1 (RIG-1) and IFN-β promoter stimulator-1 (IPS-1) significantly down-regulated in the severe coronavirus disease 2019 (COVID-19). Mol Biol Rep. 2023; 50(1): 907-911. DOI: 10.1007/s11033-022-07981-2

Ziegler CG, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020; 181(5): 1016-1035. e19. DOI: 10.1016/j.cell.2020.04.035

Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. DOI: 10.3389/fimmu.2020.01061

Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020; 28(3): 455-464.E2. DOI: 10.1016/j.chom.2020.07.005

Letafati A, Aghamirmohammadali FS, Rahimi‐Foroushani A, Hasani SA, Mokhtari‐Azad T, and Yavarian J. No human respiratory syncytial virus but SARS‐CoV‐2 found in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran. J Med Virol. 2022; 94(7): 3096-3100. DOI: 10.1002/jmv.27685

Payne S. Chapter 17 - Family Coronaviridae. Viruses. From Understanding to Investigation. Academic Press, 2017. p. 149-158. DOI: 10.1016/B978-0-12-803109-4.00017-9

Wu Z, and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242. DOI: 10.1001/jama.2020.2648

Zalinger ZB, Elliott R, Rose KM, and Weiss SR. MDA5 is critical to host defense during infection with murine Coronavirus. J Virol. 2015; 89(24): 12330-12340. DOI: 10.1128/jvi.01470-15

Huang X, Li Y, Deng J, Tan X, Yang S, Liu J, et al. A biosafe mouse model for SARS-CoV-2 infection that more realistically simulates COVID-19 symptoms. Sig Transduct Target Ther. 2026; 11: 97. DOI: 10.1038/s41392-026-02640-5

Marx S, Kümmerer BM, Grützner C, Kato H, Schlee M, Renn M, Bartok E, and Hartmann G. RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection. Mol Ther Nucleic Acids. 2022; 27: 1225-1234. DOI: 10.1016/j.omtn.2022.02.008

Shin H, Kim S, Jo A, Won J, Gil CH, Yoon SY, et al. Intranasal inoculation of IFN-λ resolves SARS-CoV-2 lung infection via the rapid reduction of viral burden and improvement of tissue damage. Front Immunol. 2022; 13: 1009424. DOI: 10.3389/fimmu.2022.1009424